Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 24 February - 3 March, 2009.
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency ARHCC Cancer Info Ctr | Available |
"Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia…
Table of Contents:; Introduction; Here to help; Your child - the initial diagnosis; Your child - coping with change; Parents - coming to terms with your feelings; Siblings - helping them cope too; Communicating with your extended family and friends; The new normal; More information
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr Missing | Available |
Content:; Melanoma / Ali Al-Haseni and Debjani Sahni -- Squamous cell carcinoma / Ali Al-Haseni and Debjani Sahni -- Basal cell carcinoma / Ali Al-Haseni and Debjani Sahni -- Cutaneous lymphoma / Bilal Fawaz and Debjani Sahni -- Kaposi's sarcoma / Bilal Fawaz and Debjani Sahni -- Dermatofibrosarcom…
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2-9 June, 2009.
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
"This poster presents the target organs for all agents classified as carcinogenic to humans (Group 1) by the IARC Monographs Programme (in red), and for the interventions showing sufficient evidence of a cancer-preventive effect in the IARC Handbooks of Cancer Prevention (in green)."
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 17-24 March, 2009.
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |